Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients.

@article{Sudlow2009ThienopyridineDV,
  title={Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients.},
  author={Cathie Sudlow and Gillian I. Mason and James Maurice and Catherine J. Wedderburn and Graeme J Hankey},
  journal={The Cochrane database of systematic reviews},
  year={2009},
  volume={4},
  pages={
          CD001246
        }
}
  • Cathie Sudlow, Gillian I. Mason, +2 authors Graeme J Hankey
  • Published 2009
  • Medicine
  • The Cochrane database of systematic reviews
  • BACKGROUND Aspirin is the most widely studied and prescribed antiplatelet agent for preventing serious vascular events, reducing the odds of such events among high vascular risk patients by about a quarter. Thienopyridine derivatives inhibit platelet activation by a different mechanism and so may be more effective. OBJECTIVES To determine the effectiveness and safety of thienopyridine derivatives (ticlopidine and clopidogrel) versus aspirin for preventing serious vascular events (stroke… CONTINUE READING

    Citations

    Publications citing this paper.
    SHOWING 1-10 OF 34 CITATIONS, ESTIMATED 32% COVERAGE

    Antiplatelets in stroke prevention.

    VIEW 2 EXCERPTS
    CITES BACKGROUND

    FILTER CITATIONS BY YEAR

    2010
    2018

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 59 REFERENCES

    Stroke prevention--insights from incoherence.